Description

Tyroserleutide (YSL), isolated from the degradation products of porcine spleen[1], is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo[2].—Cancer-programmed cell death–C18H27N3O6—-[1]Che X, Lu R, Fu Z, et al. Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SK-HEP-1 and its mechanism affecting ICAM-1 and MMP-2 and -9. Drug Des Devel Ther. 2018;12:3357-3368. |[2]Yao Z, Qiu S, Wang L, et al. Tripeptide tyroserleutide enhances the antitumor effects of macrophages and stimulates macrophage secretion of IL-1beta, TNF-alpha, and NO in vitro. Cancer Immunol Immunother. 2006;55(1):56-60. |[3]Ma C, Wei T, Hua Y, Wang Z, Zhang L. Effective Antitumor of Orally Intestinal Targeting Penetrating Peptide-Loaded Tyroserleutide/PLGA Nanoparticles in Hepatocellular Carcinoma. Int J Nanomedicine. 2021;16:4495-4513.|[4]Wang C, et al. Studies on the large scale synthesis and anti-tumor activity of YSL. Prep Biochem Biotechnol. 2003 Aug;33(3):189-95.|[5]Liang P, et al. pH-Triggered Conformational Change of Antp-Based Drug Delivery Platform for Tumor Treatment with Combined Photothermal Therapy and Chemotherapy. Adv Healthc Mater. 2019 Aug;8(15):e1900306.–138168-48-6–381.42—-CC(C)C[C@@H](C(O)=O)NC([C@H](CO)NC([C@@H](N)CC1=CC=C(O)C=C1)=O)=O–Cancer–H2O–Others—-Others–Peptides